{
    "clinical_study": {
        "@rank": "122868", 
        "acronym": "RANBI", 
        "arm_group": {
            "arm_group_label": "Natrelle\u00ae 410", 
            "description": "Subjects receiving primary breast augmentation with Natrelle\u00ae 410 cohesive BIOCELL\u2122 textured device"
        }, 
        "brief_summary": {
            "textblock": "Retrospective multi-center, post-marketing study to evaluate the incidence and etiology of\n      reoperations with Allergan Natrelle\u00ae Breast Implants in primary augmentation (RANBI)"
        }, 
        "brief_title": "Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle\u00ae Breast Implants", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Implantation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary breast augmentation (either bilateral or unilateral) operated on by the\n             investigating surgeon with an infra-mammary approach 410 cohesive BIOCELL\u2122 textured\n             device (Truform 2 & 3 only) has been implanted\n\n          -  Primary breast augmentation 3 to 10 years prior to data collection\n\n          -  Submuscular/dual plane or subglandular implant placement\n\n        Exclusion Criteria:\n\n          -  Breast augmentation for Poland Syndrome or amastia\n\n          -  Breast reconstruction following mastectomy\n\n          -  Revision or secondary breast reconstruction\n\n          -  Non 410 device at initial breast augmentation\n\n          -  Women subsequently diagnosed with fibrocystic disease considered to be pre-malignant\n\n          -  Procedures of the breast not related to the primary breast augmentation (e.g.\n             excision of skin lesions)\n\n          -  Axillary or peri-areolar approach\n\n          -  Glandular mastopexy augmentation (skin excision only)"
            }, 
            "gender": "Female", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects that have undergone a primary breast augmentation for aesthetic reasons with a\n        BIOCELL\u2122 textured 410 cohesive implant"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132572", 
            "org_study_id": "MAG-AGN-MED-BRE-003"
        }, 
        "intervention": {
            "arm_group_label": "Natrelle\u00ae 410", 
            "description": "Surgical implant", 
            "intervention_name": "NATRELLE\u00ae 410 Breast Implants", 
            "intervention_type": "Device", 
            "other_name": "Anatomical, silicone-filled breast implants (low height/projection or extra high projection)"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "D\u00fcsseldorf", 
                    "country": "Germany", 
                    "state": "North Rhine-Westphalia"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Retrospective Multi-centre, Post-marketing Study to Evaluate the Incidence and Aetiology of Reoperations With Allergan Natrelle\u00ae Breast Implants in Primary Augmentation (RANBI)", 
        "overall_contact": {
            "email": "devicetrials@allergan.com", 
            "last_name": "Allergan Medical"
        }, 
        "overall_official": {
            "affiliation": "Allergan Medical", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Conseil National de l'Ordre des M\u00e9decins", 
                "Israel: Ethics Commission", 
                "Israel: Ministry of Health", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
                "Spain: Ethics Committee", 
                "United Kingdom: National Institute for Health Research"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cumulative incidence (i.e., incidence proportion) of first reoperation following the use of a BIOCELL\u2122 textured 410 cohesive device.", 
            "safety_issue": "Yes", 
            "time_frame": "3 to 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132572"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}